(Q38585518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Oxidative stress in chronic vascular disease: From prediction to prevention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Damiano D'Ardes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Giovanni Davì

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

10 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

23-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

Oxidative stress in vascular disease and its pharmacological prevention.

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Isoprostane, an "intermediate phenotype" for oxidative stress heritability, risk trait associations, and the influence of chromogranin B polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

A Continuous Metabolic Syndrome Score Is Associated with Specific Biomarkers of Inflammation and CVD Risk in Prepubertal Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Uric acid: the oxidant-antioxidant paradox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Vitamin C prevents DNA damage induced by renovascular hypertension in multiple organs of Wistar rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Role of vitamin C in the function of the vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effect of antioxidant vitamin supplementation on endothelial function in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Vitamin E inadequacy in humans: causes and consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of vitamin E on peroxisome proliferator-activated receptor γ and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

ATVB in focus: redox mechanisms in blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients with Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Indices of lipid peroxidation in vivo: strengths and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Soluble forms of RAGE in human diseases: clinical and therapeutical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Platelet activation in obesity and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

RAGE and its ligands in cancer – culprits, biomarkers, or therapeutic targets?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidant stress, inflammation and atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Determinants of F2-isoprostane biosynthesis and inhibition in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

F2-isoprostanes as an indicator and risk factor for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Isoprostane formation and inhibition in atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Determinants of platelet activation in hypertensives with microalbuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Platelet activation in obese women: role of inflammation and oxidant stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Determinants of increased cardiovascular disease in obesity and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Dietary patterns are associated with plasma F₂-isoprostanes in an observational cohort study of adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Isoprostanes: potential markers of oxidant stress in atherothrombotic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Gastric cancer in Zambian adults: a prospective case-control study that assessed dietary intake and antioxidant status by using urinary isoprostane excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Platelet activation and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Nox-2 up-regulation and platelet activation: Novel insights

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Platelet isoprostane overproduction in diabetic patients treated with aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Endothelial dysfunction and oxidative stress in arterial hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Superoxide and peroxynitrite in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Recent changes in the landscape of combination RAS blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Reactive oxygen species and angiotensin II signaling in vascular cells -- implications in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The relationships between alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Hypertension and chronic ethanol consumption: What do we know after a century of study?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Vascular actions of nitric oxide as affected by exposure to alcohol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Vascular oxidative stress: a key factor in the development of hypertension associated with ethanol consumption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Ethanol promotes rat aortic vascular smooth muscle cell proliferation via increase of homocysteine and oxidized-low-density lipoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Ethanol withdrawal increases oxidative stress and reduces nitric oxide bioavailability in the vasculature of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Chronic ethanol ingestion induces aortic inflammation/oxidative endothelial injury and hypertension in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Ethanol consumption increases blood pressure and alters the responsiveness of the mesenteric vasculature in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Cardiovascular alterations at different stages of hypertension development during ethanol consumption: time-course of vascular and autonomic changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Chronic alcohol-induced oxidative endothelial injury relates to angiotensin II levels in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Endothelial AT₁ and AT₂ pathways in aortic responses to angiotensin II after stress and ethanol consumption in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Role of oxidative stress in endothelial insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative-induced membrane damage in diabetes lymphocytes: effects on intracellular Ca(2 +) homeostasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

p66 Shc as the engine of vascular aging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Cross-talk between SIRT1 and p66Shc in vascular diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative stress and DNA methylation regulation in the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The potential use of DNA methylation biomarkers to identify risk and progression of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Involvement of microparticles in diabetic vascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Antioxidant vitamin supplements and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Both alpha- and beta-carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of vitamin E on lipid peroxidation in healthy persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The relationship between dose of vitamin E and suppression of oxidative stress in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Nutraceuticals in diabetes and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of resveratrol and other wine polyphenols on vascular function: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Red wine extract protects against oxidative-stress-induced endothelial senescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effect of red wine consumption on biomarkers of oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Characterization of the antioxidant properties of pentaerithrityl tetranitrate (PETN)-induction of the intrinsic antioxidative system heme oxygenase-1 (HO-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Nebivolol: the somewhat-different beta-adrenergic receptor blocker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The target of metformin in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Alda-1 reduces cerebral ischemia/reperfusion injury in rat through clearance of reactive aldehydes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1+/Lin− progenitor cells in ischaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

miR-126 Is Involved in Vascular Remodeling under Laminar Shear Stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Oxidative stress drivers and modulators in obesity and cardiovascular disease: from biomarkers to therapeutic approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Endothelial microRNAs and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Type 2 diabetes as a redox disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Antioxidants accelerate lung cancer progression in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Health benefits of physical activity: the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.09.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2015.09.003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26363473%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference